Activation of the CB2 receptor system reverses amyloid-induced memory deficiency

Neurobiology of Aging

Volumn 34, Issue 3, 2013, Pages 791-804

  Wu, Jiang ^a   Bie, Bihua ^a   Yang, Hui ^a   Xu, Jijun J ^a   Brown, David L ^a   Naguib, Mohamed ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Amyloid; Astrocyte; Cannabinoid receptor type 2 (CB2); CB2 agonist; MDA7; Microglia

Indexed keywords

1 ([3 BENZYL 3 METHYL 2,3 DIHYDRO 1 BENZOFURAN 6 YL)CARBONYL]PIPERIDINE; AMYLOID BETA PROTEIN[1-40]; CANNABINOID 2 RECEPTOR AGONIST; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 1BETA; UNCLASSIFIED DRUG; 1 ((3 BENZYL 3 METHYL 2,3 DIHYDRO 1 BENZOFURAN 6 YL)CARBONYL)PIPERIDINE; 1-((3-BENZYL-3-METHYL-2,3-DIHYDRO-1-BENZOFURAN-6-YL)CARBONYL)PIPERIDINE; AMYLOID BETA PROTEIN; BENZOFURAN DERIVATIVE; CANNABINOID 2 RECEPTOR; CD11B ANTIGEN; CNR2 PROTEIN, RAT; NEUROPROTECTIVE AGENT; PIPERIDINE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CELL ACTIVATION; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG STRUCTURE; GLIA CELL; HIPPOCAMPAL CA1 REGION; IMMUNOREACTIVITY; MEMORY DISORDER; MICROGLIA; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT RESPONSE; UPREGULATION; ANIMAL; COGNITION; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; MEMORY; METABOLISM; SECRETION (PROCESS); SPRAGUE DAWLEY RAT;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTIGENS, CD11B; ASTROCYTES; BEHAVIOR, ANIMAL; BENZOFURANS; CA1 REGION, HIPPOCAMPAL; COGNITION; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN-1BETA; MEMORY; MEMORY DISORDERS; MICROGLIA; NEUROPROTECTIVE AGENTS; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB2;

EID: 84870489074     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.06.011     Document Type: Article

References (68)

1. Ahmed T., Enam S.A., Gilani A.H. Curcuminoids enhance memory in an amyloid-infused rat model of Alzheimer's disease. Neuroscience 2010, 169:1296-1306.
2. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
3. Barry A.E., Klyubin I., Mc Donald J.M., Mably A.J., Farrell M.A., Scott M., Walsh D.M., Rowan M.J. Alzheimer's disease brain-derived amyloid-β-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J. Neurosci 2011, 31:7259-7263.
4. Benito C., Kim W.K., Chavarría I., Hillard C.J., Mackie K., Tolón R.M., Williams K., Romero J. A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. J. Neurosci 2005, 25:2530-2536.
5. Benito C., Núñez E., Tolón R.M., Carrier E.J., Rábano A., Hillard C.J., Romero J. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci 2003, 23:11136-11141.
6. Benito C., Tolón R.M., Pazos M.R., Núñez E., Castillo A.I., Romero J. Cannabinoid CB2 receptors in human brain inflammation. Br. J. Pharmacol 2008, 153:277-285.
7. Bie B., Brown D.L., Naguib M. Increased synaptic GluR1 subunits in the anterior cingulate cortex of rats with peripheral inflammation. Eur. J. Pharmacol 2011, 653:26-31.
8. Bie B., Brown D.L., Naguib M. Synaptic plasticity and pain aversion. Eur. J. Pharmacol 2011, 667:26-31.
9. Bie B., Zhang Z., Cai Y.Q., Zhu W., Zhang Y., Dai J., Lowenstein C.J., Weinman E.J., Pan Z.Z. Nerve growth factor-regulated emergence of functional delta-opioid receptors. J. Neurosci 2010, 30:5617-5628.
10. Bie B., Zhu W., Pan Z.Z. Ethanol-induced delta-opioid receptor modulation of glutamate synaptic transmission and conditioned place preference in central amygdala. Neuroscience 2009, 160:348-358.
11. Bie B., Zhu W., Pan Z.Z. Rewarding morphine-induced synaptic function of delta-opioid receptors on central glutamate synapses. J. Pharmacol. Exp. Ther 2009, 329:290-296.
12. Bliss T.V., Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993, 361:31-39.
13. Cameron B., Landreth G.E. Inflammation, microglia, and Alzheimer's disease. Neurobiol. Dis 2010, 37:503-509.
14. Chacón M.A., Barría M.I., Soto C., Inestrosa N.C. Beta-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits. Mol. Psychiatry 2004, 9:953-961.
15. Chen B., Bromley-Brits K., He G., Cai F., Zhang X., Song W. Effect of synthetic cannabinoid HU210 on memory deficits and neuropathology in Alzheimer's disease mouse model. Curr. Alzheimer Res 2010, 7:255-261.
16. Diaz P., Phatak S.S., Xu J., Fronczek F.R., Astruc-Diaz F., Thompson C.M., Cavasotto C.N., Naguib M. 2,3-Dihydro-1-benzofuran derivatives as a series of potent selective cannabinoid receptor 2 agonists: design, synthesis, and binding mode prediction through ligand-steered modeling. Chemmedchem 2009, 4:1615-1629.
17. Edison P., Archer H.A., Gerhard A., Hinz R., Pavese N., Turkheimer F.E., Hammers A., Tai Y.F., Fox N., Kennedy A., Rossor M., Brooks D.J. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol. Dis 2008, 32:412-419.
18. Ehrhart J., Obregon D., Mori T., Hou H., Sun N., Bai Y., Klein T., Fernandez F., Tan J., Shytle R.D. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflammation 2005, 2:29.
19. Eikelenboom P., Veerhuis R., Scheper W., Rozemuller A.J., van Gool W.A., Hoozemans J.J. The significance of neuroinflammation in understanding Alzheimer's disease. J. Neural Transm 2006, 113:1685-1695.
20. El Khoury J., Hickman S.E., Thomas C.A., Cao L., Silverstein S.C., Loike J.D. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 1996, 382:716-719.
21. Eng L.F. Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes. J. Neuroimmunol 1985, 8:203-214.
22. Esposito G., Iuvone T., Savani C., Scuderi C., De Filippis D., Papa M., Di Marzo V., Steardo L. Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence. J. Pharmacol. Exp. Ther 2007, 322:1144-1152.
23. Facchinetti F., Del Giudice E., Furegato S., Passarotto M., Leon A. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia 2003, 41:161-168.
24. Fernández-López D., Martínez-Orgado J., Nuñez E., Romero J., Lorenzo P., Moro M.A., Lizasoain I. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Pediatr. Res 2006, 60:169-173.
25. Fernández-Ruiz J., Romero J., Velasco G., Tolón R.M., Ramos J.A., Guzmán M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival?. Trends Pharmacol. Sci 2007, 28:39-45.
26. Gabay C., Lamacchia C., Palmer G. IL-1 pathways in inflammation and human diseases. Nat. Rev. Rheumatol 2010, 6:232-241.
27. Garrison C.J., Dougherty P.M., Kajander K.C., Carlton S.M. Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injury. Brain Res 1991, 565:1-7.
28. Griffin W.S., Stanley L.C., Ling C., White L., MacLeod V., Perrot L.J., White C.L., Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:7611-7615.
29. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
30. Hickman S.E., Allison E.K., El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci 2008, 28:8354-8360.
31. Hsieh H., Boehm J., Sato C., Iwatsubo T., Tomita T., Sisodia S., Malinow R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 2006, 52:831-843.
32. Kettenmann H., Hanisch U.K., Noda M., Verkhratsky A. Physiology of microglia. Physiol. Rev 2011, 91:461-553.
33. Klyubin I., Walsh D.M., Cullen W.K., Fadeeva J.V., Anwyl R., Selkoe D.J., Rowan M.J. Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur. J. Neurosci 2004, 19:2839-2846.
34. Lai A.Y., Swayze R.D., El-Husseini A., Song C. Interleukin-1 beta modulates AMPA receptor expression and phosphorylation in hippocampal neurons. J. Neuroimmunol 2006, 175:97-106.
35. Li J., Wang Y.J., Zhang M., Fang C.Q., Zhou H.D. Cerebral ischemia aggravates cognitive impairment in a rat model of Alzheimer's disease. Life Sci 2011, 89:86-92.
36. Lynch M.A. Long-term potentiation and memory. Physiol. Rev 2004, 84:87-136.
37. Masliah E. Neuropathology: Alzheimer's in real time. Nature 2008, 451:638-639.
38. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
39. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
40. Meda L., Baron P., Scarlato G. Glial activation in Alzheimer's disease: the role of Abeta and its associated proteins. Neurobiol. Aging 2001, 22:885-893.
41. Milton N.G. Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci. Lett 2002, 332:127-130.
42. Moore A.H., Wu M., Shaftel S.S., Graham K.A., O'Banion M.K. Sustained expression of interleukin-1beta in mouse hippocampus impairs spatial memory. Neuroscience 2009, 164:1484-1495.
43. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
44. Naguib M., Diaz P., Xu J.J., Astruc-Diaz F., Craig S., Vivas-Mejia P., Brown D.L. MDA7: A novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models. Br. J. Pharmacol 2008, 155:1104-1116.
45. Naguib M., Xu J.J., Diaz P., Brown D.L., Cogdell D., Bie B., Hu J., Craig S., Hittelman W.N. Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system. Anesth. Analg 2012, 114:1104-1120.
46. Neniskyte U., Neher J.J., Brown G.C. Neuronal death induced by nanomolar amyloid β is mediated by primary phagocytosis of neurons by microglia. J. Biol. Chem 2011, 286:39904-39913.
47. Núñez E., Benito C., Pazos M.R., Barbachano A., Fajardo O., González S., Tolón R.M., Romero J. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse 2004, 53:208-213.
48. Palop J.J., Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci 2010, 13:812-818.
49. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, New York. fourth ed.
50. Perry V.H., Nicoll J.A.R., Holmes C. Microglia in neurodegenerative disease. Nat. Rev. Neurol 2010, 6:193-201.
51. Ramírez B.G., Blázquez C., Gómez del Pulgar T., Guzmán M., de Ceballos M.L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci 2005, 25:1904-1913.
52. Rogers J., Strohmeyer R., Kovelowski C.J., Li R. Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia 2002, 40:260-269.
53. Schmid A.W., Lynch M.A., Herron C.E. The effects of IL-1 receptor antagonist on beta amyloid mediated depression of LTP in the rat CA1 in vivo. Hippocampus 2009, 19:670-676.
54. Sheng W.S., Hu S., Min X., Cabral G.A., Lokensgard J.R., Peterson P.K. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 2005, 49:211-219.
55. Shin R.W., Ogino K., Kondo A., Saido T.C., Trojanowski J.Q., Kitamoto T., Tateishi J. Amyloid beta-protein (Abeta) 1-40 but not Abeta1-42 contributes to the experimental formation of Alzheimer disease amyloid fibrils in rat brain. J. Neurosci 1997, 17:8187-8193.
56. Shipton O.A., Leitz J.R., Dworzak J., Acton C.E., Tunbridge E.M., Denk F., Dawson H.N., Vitek M.P., Wade-Martins R., Paulsen O., Vargas-Caballero M. Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J. Neurosci 2011, 31:1688-1692.
57. Sims J.E., March C.J., Cosman D., Widmer M.B., MacDonald H.R., McMahan C.J., Grubin C.E., Wignall J.M., Jackson J.L., Call S.M., et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 1988, 241:585-589.
58. Song C., Phillips A.G., Leonard B.E., Horrobin D.F. Ethyl-eicosapentaenoic acid ingestion prevents corticosterone-mediated memory impairment induced by central administration of interleukin-1beta in rats. Mol. Psychiatry 2004, 9:630-638.
59. Srivareerat M., Tran T.T., Salim S., Aleisa A.M., Alkadhi K.A. Chronic nicotine restores normal Aβ levels and prevents short-term memory and E-LTP impairment in Aβ rat model of Alzheimer's disease. Neurobiol. Aging 2011, 32:834-844.
60. Stella N. Cannabinoid signaling in glial cells. Glia 2004, 48:267-277.
61. Stéphan A., Laroche S., Davis S. Generation of aggregated beta-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. J. Neurosci 2001, 21:5703-5714.
62. Streit W.J. Microglia and Alzheimer's disease pathogenesis. J. Neurosci. Res 2004, 77:1-8.
63. Tolón R.M., Núñez E., Pazos M.R., Benito C., Castillo A.I., Martínez-Orgado J.A., Romero J. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res 2009, 1283:148-154.
64. van der Stelt M., Mazzola C., Esposito G., Matias I., Petrosino S., De Filippis D., Micale V., Steardo L., Drago F., Iuvone T., Di Marzo V. Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell. Mol. Life Sci 2006, 63:1410-1424.
65. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., Stella N., Makriyannis A., Piomelli D., Davison J.S., Marnett L.J., Di Marzo V., Pittman Q.J., Patel K.D., Sharkey K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310:329-332.
66. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat. Med 2006, 12:1005-1015.
67. Yan P., Hu X., Song H., Yin K., Bateman R.J., Cirrito J.R., Xiao Q., Hsu F.F., Turk J.W., Xu J., Hsu C.Y., Holtzman D.M., Lee J.M. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J. Biol. Chem 2006, 281:24566-24574.
68. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., Schmidt A.M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996, 382:685-691.